Document is current
Any future updates will be listed below
-
Authors
Thomas, Sharyn
Mohammed, Fiyaz
Reijmers, Rogier M. https://orcid.org/0000-0001-7471-7715
Woolston, Annemarie https://orcid.org/0000-0002-8932-2895
Stauss, Theresa
Kennedy, Alan https://orcid.org/0000-0003-0384-3866
Stirling, David https://orcid.org/0000-0001-6802-4103
Holler, Angelika
Green, Louisa https://orcid.org/0000-0002-7780-3536
Jones, David https://orcid.org/0000-0001-8626-3765
Matthews, Katherine K.
Price, David A. https://orcid.org/0000-0001-9416-2737
Chain, Benjamin M. https://orcid.org/0000-0002-7417-3970
Heemskerk, Mirjam H. M. https://orcid.org/0000-0001-6320-9133
Morris, Emma C. https://orcid.org/0000-0003-4834-1130
Willcox, Benjamin E. https://orcid.org/0000-0002-6113-2109
Stauss, Hans J. https://orcid.org/0000-0003-4340-7911
- License Information
-
More Information
Article History
Received: 23 November 2018
Accepted: 26 August 2019
First Online: 1 October 2019
Competing interests
: H.J.S. is share holder of Cell Medica and obtained research funding from Cell Medica and Apollo Ltd. H.J.S. and E.M. are founders, consultants, and share holders of Quell Therapeutics. S.T., F.M., B.E.W., and H.J.S. are inventors of a patent of the dominant TCR technology. The remaining authors declare no competing interests.
